ADIA Med Nearly Doubles Nine-Month Revenue to Surpass $1 Million
ADIA Med nearly doubled revenue but remains unprofitable amid ongoing investment and expansion.
What the company is saying
ADIA Med, Inc. reports a 95% year-over-year increase in nine-month revenue to $1,019,245, surpassing $1 million for the first time. The company highlights that medical procedure revenue more than doubled and frames the sale of a 30% interest in Adia Labs LLC for $1,500,000 as a strengthening of the balance sheet while retaining majority ownership. CEO Larry Powalisz emphasizes ongoing efforts to build the platform and achieve profitability, stating the company will continue investing in its medical and biologics operations. The announcement spotlights operational growth, improved cash position, and strategic partnerships, but acknowledges continued net losses as a result of investment in growth. The tone is optimistic, focusing on scaling and future clinical studies targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with additional studies planned for 2026. The company also notes the full repayment of its unsecured revolving line of credit with the CEO after quarter end.
What the data suggests
Revenue for the nine months ended September 30, 2026 rose 95% to $1,019,245 from $521,958, while third-quarter revenue increased 37% year-over-year to $454,385. Gross profit for the quarter was $220,981, up from $203,485, and nine-month gross profit nearly doubled to $474,338 from $243,461. Despite these gains, the company reported a third-quarter net loss of $53,015, reversing a net income of $70,376 in the prior-year quarter, and a nine-month net loss of $271,922, compared to $169,839 a year earlier. Cash at quarter end was $1,137,818, with total assets of $2,452,987 and stockholders' equity of $970,404. The $1,500,000 sale of a 30% stake in Adia Labs LLC (comprised of $1,000,000 cash and a $500,000 promissory note) improved liquidity but did not deliver profitability. The company fully repaid its unsecured revolving line of credit after quarter end. No segment-level revenue or expense breakdowns are provided, and operational claims about clinical studies and product lines lack supporting quantitative detail. The data supports strong top-line growth and improved liquidity but also reveals persistent losses and ongoing capital requirements.
Analysis
The announcement presents strong revenue and gross profit growth, with headline figures supported by disclosed numbers. However, the company remains unprofitable, with net losses increasing year-over-year, and the narrative emphasizes ongoing investment and a path toward future profitability rather than current earnings. Several claims about operational scale, clinical studies, and product lines are not backed by detailed segment or product-level data. The tone is upbeat, highlighting balance sheet improvements and strategic transactions, but the realized financial progress is limited to top-line growth, not bottom-line improvement. The forward-looking statements about continued investment and future clinical studies signal that material profitability is not imminent. The capital intensity flag is triggered by explicit references to ongoing investment without immediate earnings impact.
Risk flags
- ●Sustained net losses remain a core risk, with the company reporting a nine-month net loss of $271,922 and a third-quarter net loss of $53,015 despite strong revenue growth. This indicates that expenses and investment requirements are outpacing gross profit gains, raising questions about the timeline and pathway to profitability.
- ●The company is heavily reliant on continued investment in its medical and biologics platform, as explicitly stated by management. This capital intensity means that further funding or asset sales may be needed if losses persist, and there is no disclosed timeline for achieving positive earnings.
- ●Operational and segment-level transparency is limited. While headline revenue and profit figures are disclosed, there is no detailed breakdown of revenue by product, service, or subsidiary, nor are there metrics for clinical study progress or outcomes. This lack of granularity makes it difficult to assess the sustainability and drivers of growth.
- ●The company’s strategic partnership involved selling a 30% interest in Adia Labs LLC for $1,500,000 ($1,000,000 cash and a $500,000 promissory note), but future cash flows from the promissory note are subject to counterparty performance risk. The company retains majority ownership, but the long-term impact on operational control and future earnings is not quantified.
Bottom line
ADIA Med, Inc. delivered rapid revenue and gross profit growth in the first nine months of 2026, with revenue up 95% to $1,019,245 and a significant balance sheet boost from the $1,500,000 Adia Labs transaction. Despite these improvements, the company remains unprofitable, posting a nine-month net loss of $271,922 and a third-quarter net loss of $53,015, reflecting ongoing investment in scaling its medical and biologics platform. The repayment of its unsecured revolving line of credit and a cash balance of $1,137,818 provide some financial stability, but the absence of a clear path or timeline to profitability, and limited segment-level disclosure, leave material uncertainties. Management’s focus on future clinical studies and platform expansion signals that further capital and time will be required before sustainable earnings are achieved. Investors should focus on the company’s ability to convert revenue growth into profitability and monitor for more granular financial and operational disclosures in future updates. The most important takeaway is that while top-line momentum is strong, bottom-line improvement and operational transparency remain unresolved.
Track record
NewsStack has analysed 20 announcements from ADIA since April 2026.
Previous ADIA verdicts
- 13 Oct 2026Mild PositiveAdia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position
- 31 Aug 2026Likely OverhypedFrom Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team
- 24 Aug 2026Likely OverhypedAdia Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting
- 13 Aug 2026Likely OverhypedAdia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
- 11 Aug 2026Routine NoiseAdia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing
Announcement summary
(OTCQB:ADIA) ADIA Med, Inc. reported that revenue for the nine months ended September 30, 2026 rose approximately 95% to $1,019,245, up from $521,958 in the same period last year, surpassing the $1 million mark. Medical procedure revenue more than doubled year-over-year in the first nine months. The Adia Labs transaction strengthened the company's balance sheet as operations continue to scale. Third-quarter revenue increased approximately 37% to $454,385, from $332,048 a year earlier. Third-quarter gross profit grew to $220,981, from $203,485 in the prior-year quarter. Nine-month gross profit nearly doubled to $474,338, from $243,461 in the comparable 2025 period. As of September 30, 2026, cash stood at $1,137,818, with total assets of $2,452,987 and stockholders' equity of $970,404. On September 30, 2026, ADIA Med sold a 30% membership interest in Adia Labs LLC to Live Oak Health LLC (d/b/a QCM Biologics) for $1,500,000, consisting of $1,000,000 cash and a $500,000 promissory note, while retaining majority ownership. After quarter end, the company fully repaid and discharged its unsecured revolving line of credit facility with its Chief Executive Officer. For the third quarter, the company reported a net loss of $53,015, compared with net income of $70,376 in the third quarter of 2025. For the first nine months of 2026, the net loss was $271,922, compared with $169,839 a year earlier, reflecting continued investment in growth. The company expects to continue investing in its medical and biologics platform as it works toward profitability. The company's Quarterly Report on Form 10-Q for the period ended September 30, 2026 is available online. Larry Powalisz is the Chief Executive Officer of ADIA Med. Adia Med clinics deliver stem cell treatments and complementary services such as platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT), supported by multiple Institutional Review Board (IRB)-approved clinical studies. Current studies are targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with more planned for 2026. The Adia Labs division manufactures regenerative products (AdiaVita, AdiaLink) that supply clinical work. Adia Labs generates revenue by manufacturing and selling regenerative products to Adia Med clinics and external providers. Adia Med clinics generate revenue through patient treatments. Additional revenue comes from the company's 18% equity stake in Cement Factory LLC and from ADIA Life LLC's wellness product distribution.
Disagree with this article?
Ctrl + Enter to submit